p>"We have woken up to the fact that people expect to know how [approved] devices perform."

— Daniel Schultz, commenting on the FDA's increased emphasis on post-approval surveillance, CDRH's Schultz outlines his 2008 action plan for agency," pp. 1, 5.

No Comments